Flt3 ligand improves the innate response to respiratory syncytial virus and limits lung disease upon RSV reexposure in neonate mice. Issue 4 (22nd January 2016)

• Record Type: Journal Article
• Authors: Remot, Aude; Descamps, Delphyne; Jouneau, Luc; Laubreton, Daphné; Dubuquoy, Catherine; Bouet, Stephan; Lecardonnel, Jérôme; Rebours, Emmanuelle; Petit‐Camurdan, Agnès; Riffault, Sabine
• Is Part Of: European journal of immunology. Volume 46:Issue 4(2016)
• Page Start: 874
• Page End: 884
• Publication Date: 2016-01-22
• Subjects: Dendritic cells -- Flt3‐L -- Interferon -- Lung -- Neonate -- Respiratory syncytial virus; Immunology -- Periodicals; 616.079
• DOI: 10.1002/eji.201545929
• Languages: English
• ISSNs: 0014-2980

Abstract

Abstract : Immunomodulation with Flt3 ligand (Flt3‐L) enhances innate immunity to respiratory syncytial virus (RSV) infection in neonatal lungs (DCs and IFN‐I). Flt3‐L‐mediated immune modulation further prevents airway‐exacerbated pathology upon adult reexposure to RSV. Abstract : Respiratory syncytial virus (RSV) causes severe bronchiolitis in infants worldwide. The immunological factors responsible for RSV susceptibility in infants are poorly understood. Here, we used the BALB/c mouse model of neonatal RSV infection to study the mechanisms leading to severe disease upon reexposure to the virus when adults. Two major deficiencies in neonatal lung innate responses were found: a poor DCs mobilization, and a weak engagement of the IFNI pathway. The administration of Flt3 ligand (Flt3‐L), a growth factor that stimulates the proliferation of hematopoietic cells, to neonates before RSV‐infection, resulted in increased lung DC number, and reconditioned the IFNI pathway upon RSV neonatal infection. Besides, neonates treated with Flt3‐L were protected against exacerbated airway disease upon adult reexposure to RSV. This was associated with a reorientation of RSV‐specific responses toward Th1‐mediated immunity. Thus, the poor lung DCs and IFNI responses to RSV in neonates may be partly responsible for the deleterious long‐term consequences revealed upon adult reexposure to RSV, which could be prevented by Flt3‐L treatment. These results open new perspectives for developing neonatal immuno‐modulating strategies to reduce the burden of bronchiolitis.